Galectin Therapeutics has reported a net loss of $2.54m, or $0.72 per share, for the second quarter ended on 30 June 2013 compared to a net loss of $2.66m, or $0.19 per share, in 2012. Total operating loss for the second quarter ended 30 ...
Galectin Therapeutics will move its corporate offices to Atlanta, Georgia, US, by 1 October 2012 while maintaining a laboratory-based effort in the Boston area. The move will bring Galectin Therapeutics closer to its collaborator, Complex ...
Tags: galectin therapeutics, atlanta, collaborator
The USPTO has granted Galectin Therapeutics a notice of issuance for a patent covering methods of derivation and use for carbohydrate-based galectin inhibitor compound for use in patients with chronic liver disease associated with the ...
Tags: Galectin, US patent, disease therapy